AOD-9604 vs Cagrilintide
A side-by-side research comparison of AOD-9604 and Cagrilintide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AOD-9604 | Cagrilintide |
|---|---|---|
| Full name | Advanced Obesity Drug Fragment 176-191 (Modified) | Cagrilintide (AM833) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Investigational (Phase III) |
| Mechanism | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. | Acts as a dual amylin and calcitonin receptor agonist. It engages satiety centers in the area postrema and hindbrain, reducing food intake and slowing gastric emptying through a pathway distinct from GLP-1. |
| Molecular weight | 1815.08 Da | ~3963 Da |
| Half-life | ~2-3 hours | ~7-8 days |
| Bioavailability | ~90% subcutaneous | High via subcutaneous injection |
| Typical dose | 300 mcg | 0.3-2.4 mg (titrated) |
| Frequency | Daily (morning, fasted) | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Cagrilintide reported benefits
- Appetite suppression and increased satiety
- Meaningful weight loss
- Complements GLP-1 agonists (additive effect)
- Slows gastric emptying
Related comparisons
Research and educational reference only. Not medical advice.